More ongoing results in combination with Keytruda.
Continuing on its quest to grow Keytruda’s blockbuster status ahead of a 2028 patent cliff, Merck reported today that Keytruda has missed in two indications — as a first-line therapy in combination with Eisai’s Lenvima for liver cancer, and also as a later-line treatment for metastatic prostate cancer.
https://endpts.com/despite-5b-sales-for-keytruda-merck-hits-two-phiii-snags-as-it-continues-to-build-its-multibillion-dollar-drug/
Media Thread, page-6209
-
- There are more pages in this discussion • 9,227 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.002(3.57%) |
Mkt cap ! $401.6M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.7¢ | 5.4¢ | $1.182M | 21.47M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 3441484 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 574188 | 6 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |